In the United States,<unk>  is indicated for the treatment of people with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). In the European Union,<unk>  is indicated for long-term enzyme replacement therapy in people with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.
Asfotase alfa
Velmanase alfa
Sebelipase alfa
Angiozyme
Desmoteplase
Anistreplase
Lusutrombopag
Celadrin 